Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q1

4574.TEDINET S100TDKT
Period2024-01-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥1.4bn2024-01-01 → 2024-03-31Cons.Net sales
Revenue¥6.1bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥1.2bn2023-01-01 → 2023-03-31Cons.Net sales
Operating income¥214m2024-01-01 → 2024-03-31Cons.Operating income
Operating income−¥155m2023-01-01 → 2023-03-31Cons.Operating income
Ordinary income¥229m2024-01-01 → 2024-03-31Cons.Ordinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥242m2023-01-01 → 2023-03-31Cons.Ordinary income
Profit before tax¥429m2024-01-01 → 2024-03-31Cons.Income before income taxes
Profit before tax−¥242m2023-01-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥472m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥3.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥243m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income¥472m2024-01-01 → 2024-03-31Cons.Profit loss
Net income−¥243m2023-01-01 → 2023-03-31Cons.Profit loss
Total assets¥13.0bnat 2024-03-31Cons.Assets
Total assets¥13.2bnat 2023-12-31Cons.Assets
Total assets¥14.4bnat 2023-03-31Cons.Total assets (5-year summary)
Total liabilities¥5.6bnat 2024-03-31Cons.Liabilities
Total liabilities¥6.5bnat 2023-12-31Cons.Liabilities
Net assets / equity¥7.4bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥7.9bnat 2023-03-31Cons.Net assets (5-year summary)
Cash and deposits¥5.2bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥5.5bnat 2023-12-31Cons.Cash and deposits
EPS (basic)¥9.412024-01-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-76.252023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.592023-01-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio57.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio51.0%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥207m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥140m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥140m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥64m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2024-01-01 → 2024-03-31−¥2m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥1.2bn
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥1.2bn
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-03-31¥489m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-03-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-03-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-03-31¥421m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥241m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥124m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-03-31−¥5m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥215m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31¥85m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 353
ItemContextValueUnit
Refund liabilities clPrior1YearInstant72000000JPY
Refund liabilities clCurrentQuarterInstant66000000JPY
Provision for bonusesPrior1YearInstant75000000JPY
Provision for bonusesCurrentQuarterInstant26000000JPY
Provision for loss on subleases clPrior1YearInstant48000000JPY
Provision for loss on subleases clCurrentQuarterInstant20000000JPY
Asset retirement obligations clPrior1YearInstant203000000JPY
Asset retirement obligations clCurrentQuarterInstant17000000JPY
Other clPrior1YearInstant281000000JPY
Other clCurrentQuarterInstant206000000JPY
Current liabilitiesPrior1YearInstant3046000000JPY
Current liabilitiesCurrentQuarterInstant2500000000JPY
Long term loans payablePrior1YearInstant1999000000JPY
Long term loans payableCurrentQuarterInstant1627000000JPY
Long term accounts payable otherPrior1YearInstant549000000JPY
Long term accounts payable otherCurrentQuarterInstant549000000JPY
Provision for loss on subleases nclPrior1YearInstant28000000JPY
Provision for loss on subleases nclCurrentQuarterInstant24000000JPY
Net defined benefit liabilityPrior1YearInstant624000000JPY
Net defined benefit liabilityCurrentQuarterInstant635000000JPY
Asset retirement obligations nclPrior1YearInstant20000000JPY
Asset retirement obligations nclCurrentQuarterInstant20000000JPY
Other nclPrior1YearInstant210000000JPY
Other nclCurrentQuarterInstant215000000JPY
Noncurrent liabilitiesPrior1YearInstant3433000000JPY
Noncurrent liabilitiesCurrentQuarterInstant3072000000JPY
LiabilitiesPrior1YearInstant6480000000JPY
LiabilitiesCurrentQuarterInstant5573000000JPY
Capital stockPrior1YearInstant2267000000JPY
Capital stockCurrentQuarterInstant2297000000JPY
Capital surplusPrior1YearInstant2689000000JPY
Capital surplusCurrentQuarterInstant2719000000JPY
Retained earningsPrior1YearInstant1628000000JPY
Retained earningsCurrentQuarterInstant2100000000JPY
Treasury stockPrior1YearInstant-300000000JPY
Treasury stockCurrentQuarterInstant-300000000JPY
Shareholders equityPrior1YearInstant6284000000JPY
Shareholders equityCurrentQuarterInstant6817000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant91000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant185000000JPY
Foreign currency translation adjustmentPrior1YearInstant363000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant421000000JPY
Valuation and translation adjustmentsPrior1YearInstant454000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant607000000JPY
Subscription rights to sharesPrior1YearInstant0JPY
Subscription rights to sharesCurrentQuarterInstant－JPY
Net assetsPrior1YearInstant6739000000JPY
Net assetsCurrentQuarterInstant7424000000JPY
Liabilities and net assetsPrior1YearInstant13220000000JPY
Liabilities and net assetsCurrentQuarterInstant12997000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass